PT - JOURNAL ARTICLE AU - Hong Song AU - Andrei Iagaru AU - Steven P. Rowe TI - <sup>18</sup>F DCFPyL PET Acquisition, Interpretation and Reporting: Suggestions Post Food and Drug Administration Approval AID - 10.2967/jnumed.121.262989 DP - 2021 Sep 01 TA - Journal of Nuclear Medicine PG - jnumed.121.262989 4099 - http://jnm.snmjournals.org/content/early/2021/09/15/jnumed.121.262989.short 4100 - http://jnm.snmjournals.org/content/early/2021/09/15/jnumed.121.262989.full AB - 18F-DCFPyL was recently approved by the FDA for evaluation prior to definitive therapy and for biochemical recurrence. Here we focus on the key data that justify the clinical use of 18F-DCFPyL, as well as those aspects of protocol implementation and image interpretation that are important to the nuclear medicine physicians and radiologists who will interpret 18F-DCFPyL PET/CT and PET/MR scans.